Global Breast Cancer Predictive Genetic Testing Market Outlook 2022 report analyzes the
various aspects related to the emergence and development of breast cancer genetic test
market across the globe. The current and future aspects of cancer genomics have covered a
long path of advances and the journey is still ongoing. The technological improvements in
genomic sciences had allowed parallel sequencing of both tumors and germline mutations and
had provided the weapon of next generation sequencing. Under the supervision of intellectual
property laws and appropriate guidelines cancer susceptibility testing has become one of the
major assets in medical practice. There appears to be pervasive belief in both scientific and
public circles that genetic testing is going to be the cornerstone of much, if not all, of what
medicine holds for the future. Besides, what is generally meant is the wide scale testing for
susceptibility to common diseases especially for cancer and for responsiveness to drugs has
come to be described as genetic profiling.
With the knowledge and acceptance of the fact that the breast cancer is on alarming scale,
the major concern has been diverted towards this scenario. As there are 5% to 10% of breasts
cancer cases which occur due to the germline mutations and the most common ones are the
BRCA1 and BRCA2 mutations. Fortunately, these hereditary cancers can be prevented if
diagnosed early or even before its occurrence which includes the susceptibility testing of
breast cancer genes.
Breast cancer susceptibility has been in existence since 1966 and had served as the boon for
the patients as well as the stakeholders. Certainly, 2013 have been the year of major events
in the field of predictive genetic testing as US FDA approved the use of next generation DNA
sequencing in clinical practice. Further, the decision of Supreme Court invalidated the BRCA
patent held by Myriad genetics. These decisions made the new entries and embraced the
competitions in the cancer genetics market.
Leading to the current scenario which is completely changing and the market is now
subjected to the direct to consumer BRCA testing kits provided by varied pharmaceuticals.
However, the new entrants to the global market will face considerable challenges in
persuading physicians to choose them as a test provider. New entrants will need to provide
indication of subsequent in meeting the requirements of physicians such as reputation, trust,
transparency, and counseling. Some of these aspects cannot be established quickly, and take
time to establish.
The future holds up for the precision medicine and cancer predictability will be proving a
great deal, as through the aid of breast cancer predictive testing and better counseling
measures this regimen can turn out into an effective prophylactic modality for hereditary as
well as early stage breast cancer. The predictive risk calculations will be leading towards the
better management and improved survival rates. Over the next decade or two, it seems likely
that the technology will screen entire populations or specific subgroups for genetic
information in order to target interventions to individual patients that will improve their
health and prevent disease. While the evidence base is still growing, genetic services industry
leaders strongly believe that emerging testing capabilities will have significant clinical impact
in the future.
Table of Contents
3.1.3 TP53
3.1.4 PTEN
3.2.1 CHEK2
3.2.2 PALB2
3.2.3 ATM
7.1 Surveillance
7.2 Chemoprevention
10.1.1 US
10.1.2 Europe
10.1.3 Canada
10.1.4 Japan
10.2.1 China
10.2.2 India
10.2.3 Africa
13.2 Challenges
14. Global Breast Cancer Predictive Genetic Testing Market Future Aspects
15.2 Invitae
15.5 NeoGenomics
15.6 Oncocyte
15.7 PerkinElmer
15.9 Roche
List of Figures
Figure 12-1: Myriads - Market Sales for BRCA Testing (US$ Millions)
Figure 12-2: Criticism for the BRCA Testing Genes Patented by Myriad Genetics
Figure 12-3: The Cost Comparison of Myriads BRCA Testing & Other Competitors (US$)
Figure 12-4: Price Difference between Healthcare BRCA Testing & Direct to Consumer Test
Figure 12-5: Global BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-6: US BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-7: Europe BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-8: Asia BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 13-1: Global - Major Parameters of Growth in Breast Cancer Susceptibility Testing
Figure 13-2: Global - Major Challenges of Breast Cancer Susceptibility Market
Table 4-1: High Penetrance Mutation Variants Corresponding to Breast Cancer Syndromes
Table 7-1: Schedule of Surveillance of Breast Cancer According To Age